Utilization of Gene Therapy to Develop COVID-19 Vaccines Expected to Accelerate Market Growth
2022-03-02
基因疗法新型冠状病毒感染COVID-19 vaccine (Mass General Brigham)疫苗抗体细胞疗法并购
Gene therapy encompasses an advanced medical treatment for numerous chronic and genetic disorders in humans. This is achieved by replacing a defective gene cell with a healthy gene cell. Through gene therapy, chronic and genetic disorders that do not have developed cures can be prevented. Developers of gene therapy are quickly expanding their businesses through acquisitions and mergers. New product launch deals are being signed as a strategy to strengthen product trails and augment in-house proficiency.
Onslaught of the COVID-19 pandemic has accelerated the application of gene therapy. Technology for gene and cell therapy is anticipated to be excessively applied for developing vaccines. In January 2019, Mass General Brigham developed vaccine candidates which stimulated convincing immune responses from animal models in treatment of the novel coronavirus. The vaccine candidate named AAVCOVID, was developed through gene-therapy technology and received a grant of USD 2.1 Million for further research. Similarly, researchers from the University of Pennsylvania have started using adeno-associated viral vectors to transmit lab-made antibodies into the body.
靶点
-来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。